4 hours Citigroup Begins Coverage on Celldex Therapeutics (NASDAQ:CLDX) MarketBeat
Citigroup started coverage on Celldex Therapeutics in a report on Monday. They set a “buy” rating and a $70.00 price objective for the company.
Citigroup started coverage on Celldex Therapeutics in a report on Monday. They set a “buy” rating and a $70.00 price objective for the company.